Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
31
result(s) for
"Booth, Brett"
Sort by:
Teen Titans. Vol. 2, The culling
The Teen Titans must join forces as they are pitted against each other by Harvest, the vile leader of project N.O.W.H.E.R.E.
Book
WINE McGuigan hit Grape glut forces a writedown
[McGuigan Simeon] said the writedown - of about 9 per cent of inventory - came after another large vintage in Australia and a grape harvest in the U.S. 20 per cent above forecast. McGuigan handles about 15 per cent of Australia's grape crush and, excluding contract processing, had a grape intake this year of 197,000 tonnes, down 11 per cent on 2005. Mr [Tony Keys] said Australia's top 20 winemakers should not be relying on bodies such as the Australian Wine and Brandy Corporation or the Winemakers Federation of Australia. However, the 2000 smaller wineries did need support as they targeted the U.S. and China.
Newspaper Article
Teen Titans. Vol. 1, It's our right to fight
Tim Drake, Batman's former sidekick, is back in action when an international organization called Project N.O.W.H.E.R.E. seeks to capture, kill or co-opt super-powered teenagers. As Red Robin, he's going to have to team up with the mysterious and belligerent powerhouse thief known as Wonder Girl, the hyperactive speedster calling himself Kid Flash and few more all-new teen super-heroes to stand any chance at all against N.O.W.H.E.R.E. But as Superboy meets them for the first time, the Titans have to wonder, is he a friend - or foe?
Book
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
BackgroundCemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and the pivotal Phase 2 study (NCT02760498). Here we report the primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) and provide a longer-term update after the primary analysis of weight-based cemiplimab 3 mg/kg intravenously every 2 weeks (Q2W) (Group 1) among metastatic CSCC (mCSCC) patients in the pivotal study (NCT02760498).MethodsThe primary objective for each group was objective response rate (ORR) per independent central review (ICR). Secondary endpoints included ORR by investigator review (INV), duration of response (DOR) per ICR and INV, and safety and tolerability.ResultsFor Group 3 (n=56) and Group 1 (n=59), median follow-up was 8.1 (range, 0.6 to 14.1) and 16.5 (range, 1.1 to 26.6) months, respectively. ORR per ICR was 41.1% (95% CI, 28.1% to 55.0%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 45.2% (95% CI, 35.9% to 54.8%) in both groups combined. Per ICR, Kaplan–Meier estimate for DOR at 8 months was 95.0% (95% CI, 69.5% to 99. 3%) in responding patients in Group 3, and at 12 months was 88.9% (95% CI, 69.3% to 96.3%) in responding patients in Group 1. Per INV, ORR was 51.8% (95% CI, 38.0% to 65.3%) in Group 3, 49.2% (95% CI, 35.9% to 62.5%) in Group 1, and 50.4% (95% CI, 41.0% to 59.9%) in both groups combined. Overall, the most common adverse events regardless of attribution were fatigue (27.0%) and diarrhea (23.5%).ConclusionIn patients with mCSCC, cemiplimab 350 mg intravenously Q3W produced substantial antitumor activity with durable response and an acceptable safety profile. Follow-up data of cemiplimab 3 mg/kg intravenously Q2W demonstrate ongoing durability of responses.Trial registration numberClinicaltrials.gov, NCT02760498. Registered May 3, 2016, https://clinicaltrials.gov/ct2/show/NCT02760498
Journal Article
Nightwing. Volume 4, Second City
\"Kyle Higgins sends Nightwing to the Windy City to track down his parent's killer! After the Joker's attack on the Bat-family, Nightwing finds himself in a new setting with an unlikely ally, The Prankster. Together they are being hunted by the mysterious Mask Killer while Dick tries to find the man who killed his parents, Tony Zullo. Twists and surprises are at every turn in this exciting new chapter of Nightwing! This volume collects Nightwing #19-24\"-- Provided by publisher.
Book
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
BackgroundTo provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).MethodsPatients received cemiplimab 3 mg/kg every 2 weeks (group 1, metastatic CSCC [mCSCC], n=59; group 2, locally advanced CSCC, n=78) or cemiplimab 350 mg every 3 weeks (group 3, mCSCC, n=56). Primary endpoint was objective response rate (ORR) per independent central review (ICR). QoL was repeatedly measured at day 1 of each treatment cycle (groups 1 and 2: 8 weeks; group 3: 9 weeks).ResultsMedian duration of follow-up was 15.7 months. Overall, ORR per ICR was 46.1% (95% CI: 38.9% to 53.4%). Complete response (CR) rates were 20.3%, 12.8%, and 16.1% for groups 1, 2, and 3, respectively. Median time to CR was 11.2 months. Among patients with partial response or CR, the estimated proportion of patients with ongoing response at 12 months from the first objective response was 87.8% (95% CI: 78.5% to 93.3%), with median DOR not reached. Kaplan-Meier estimated probability of overall survival (OS) was 73.3% (95% CI: 66.1% to 79.2%) at 24 months, with median OS not reached. Global Health Status (GHS)/QoL improvements were observed as early as cycle 2 and were significantly improved and durable until last assessment. Kaplan-Meier estimate of median time to first clinically meaningful improvement for pain was 2.1 (95% CI: 2.0 to 3.7) months and was significantly improved in responders versus non-responders (p<0.0001).ConclusionsThis is the largest (n=193) clinical dataset for a programmed cell death-1 inhibitor against advanced CSCC, confirming the sustained substantial clinical activity of cemiplimab in these patients, including new findings of improved CR rates over time, increasing DOR, and durable pain control and GHS/QoL improvement.Trial registration numberClinicalTrials.gov Registry (NCT02760498), https://clinicaltrialsgov/ct2/show/NCT02760498.
Journal Article
Red Hood and the Outlaws. Volume 3, Death of the Family
The Joker has returned! A year ago, the Joker had his own face removed and vanished from Gotham City--or so Batman and his allies thought. Surfacing once more, the Clown Prince goes after each member of the Bat-Family and systematically takes them down, leading to a final confrontation that will change the lives of the Dark Knight and his allies forever!
Book
Wine glut forces McGuigan writedown
Speaking to the Australia-Israel Chamber of Commerce in Adelaide yesterday, Mr [Tony Keys] said Australian wine producers should look beyond Britain for export sales because the wine boom of the 1990s was a one-off \"phenomenon\". Australia's second-largest listed wine producer, which relies on bulk wine sales for more than half of its business, decided to conduct the review as it had been affected as \"already low\" bulk wine prices fell a further 30 to 40 a litre in the past six months, Mr [Dane Hudson] said. Mr Keys told the Adelaide conference the top 20 Australian wine companies, which make 80 per cent of the nation's wine, should not need to rely on organisations such as the Australian Wine and Brandy Corporation or the Winemakers Federation of Australia.
Newspaper Article
Heroes reborn. Fantastic four
\"The Fantastic Four are Reborn, but it could be a short and unwonderful life as menaces emerge from the earth, the sea, and Latveria! But even the Mole Man, Namor and Doom himself pale before the threat of Galactus and his Heralds (one finally just wasn't enough)! Featuring the Avengers, S.H.I.E.L.D. and more! Guest-starring Wolverine and Franklin Richards, Son of a Genius!\"--Provided by publisher.
Book
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was associated with the expected spectrum of adverse events.
Journal Article